CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the early inhalation of Budesonide to reduce the risk of bronchopulmonary dysplasia or death in preterm infants. It aims to determine its effectiveness in improving survival without bronchopulmonary dysplasia at 36 weeks gestational age through a randomized clinical trial.
HYPOTHESIS:
Early inhalation of Budesonide (BS) reduces the absolute risk of developing bronchopulmonary dysplasia (BPD) or death in preterm infants born between 23 and 27 weeks gestational age (GA) by 10%.
PRIMARY
OBJECTIVE:
Survival without BPD at 36 weeks GA.
SECONDARY
OBJECTIVES: (1) neurodevelopment at a corrected age of 18-22 months; (2) adverse treatment effects; (3) mortality at 36 weeks GA; (4) BPD incidence at 36 weeks GA; (5) duration of positive pressure respiratory support or supple…
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Belfast
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Czechia, Praha 1
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Finland, Oulu
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Israel, Tel Aviv
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
